Patents by Inventor Brian J. GEIST

Brian J. GEIST has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260201029
    Abstract: Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as “RE mutations”) per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody-dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).
    Type: Application
    Filed: July 31, 2025
    Publication date: July 16, 2026
    Inventors: Bradley James Heidrich, Xiefan Lin-Schmidt, James Salvatore Testa, JR., John Patrick, Brian J. Geist, Sheng-Jiun Wu, Adam Zwolak, Ulrike Philippar
  • Publication number: 20250188163
    Abstract: Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as “RE mutations”) per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody-dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).
    Type: Application
    Filed: December 6, 2024
    Publication date: June 12, 2025
    Inventors: Bradley Heidrich, Xiefan LIN-SCHMIDT, James Salvatore TESTA, JR., John PATRICK, Brian J. GEIST, Sheng-Jiun WU, Adam ZWOLAK, Ulrike PHILIPPAR